Art

J-GLOBAL ID：202102286321265301   Reference number：21A0292048

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

非小細胞肺癌(NSCLC)における免疫チェックポイント阻害剤(ICI)療法のための臨床的に関連する予後と予測マーカー【JST・京大機械翻訳】

Author (5)： Brueckl Wolfgang M. (Department of Respiratory Medicine, Allergology and Sleep Medicine / Nuremberg Lung Cancer Center, Paracelsus Medical University, General Hospital Nuremberg, Nuremberg, Germany) ,  Brueckl Wolfgang M. (Paracelsus Medical Private University Nuremberg, Nuremberg, Germany) ,  Ficker Joachim H. (Department of Respiratory Medicine, Allergology and Sleep Medicine / Nuremberg Lung Cancer Center, Paracelsus Medical University, General Hospital Nuremberg, Nuremberg, Germany) ,  Ficker Joachim H. (Paracelsus Medical Private University Nuremberg, Nuremberg, Germany) ,  Zeitler Gloria (Paracelsus Medical Private University Nuremberg, Nuremberg, Germany)
Material： BMC Cancer (Web)
Volume： 20  Issue： 1  Page： 1-16  Publication year： 2020 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Immune checkpoint inhibitors (...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0292048&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： algorithm ,  bioinstrumentation ,  death ,  tumor ,  side effect ,  drug therapy ,  clinical trial ,  relaxation phenomenon ,  *prognosis ,  *non-small cell lung cancer ,  biomarker ,  palliative care
Semi thesaurus term： 予測因子 ,  *予測マーカー ,  *免疫チェックポイント阻害剤 , 【Automatic Indexing@JST】

Author keywords (7)： Immunotherapy ,  Immune checkpoint inhibitor (ICI) ,  PD-L1 inhibitor ,  NSCLC ,  Prognostic ,  Predictive ,  Biomarker

JST classification (2)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (167)：

• N Engl J Med; Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer; H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready; 373; 17; 2015; 1627-1639; 10.1056/NEJMoa1507643; citation_id=CR1
• Clin Transl Oncol; Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program; J Corral, M Majem, D Rodríguez-Abreu, E Carcereny, ÁA Cortes, M Llorente; 21; 9; 2019; 1270-1279; 10.1007/s12094-019-02053-7; citation_id=CR2
• Lancet.; Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial; L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, J Mazieres; 387; 10030; 2016; 1837-1846; 10.1016/S0140-6736(16)00587-0; citation_id=CR3
• Lancet.; Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial; RS Herbst, P Baas, DW Kim, E Felip, JL Perez-Gracia, JY Han; 387; 10027; 2016; 1540-1550; 10.1016/S0140-6736(15)01281-7; citation_id=CR4
• J Clin Oncol; Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057); L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins; 35; 35; 2017; 3924-3933; 10.1200/JCO.2017.74.3062; citation_id=CR5

Terms in the title (8)： 非小細胞肺癌 ,  NSCLC ,  免疫チェックポイント阻害剤 ,  ICI ,  療法 ,  臨床 ,  予後 ,  予測マーカー